<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="320874">
  <stage>Registered</stage>
  <submitdate>26/11/2009</submitdate>
  <approvaldate>10/05/2010</approvaldate>
  <actrnumber>ACTRN12610000373077</actrnumber>
  <trial_identification>
    <studytitle>A dendritic cell vaccine to suppress the immune response to citrullinated antigen in rheumatoid arthritis</studytitle>
    <scientifictitle>A phase I clinical trial to assess the safety and induction of antigen-specific tolerance of autologous modified dendritic cells exposed to citrullinated peptides (Rheumavax) in patients with rheumatoid arthritis</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>nil</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Rheumatoid arthritis</healthcondition>
    <conditioncode>
      <conditioncode1>Musculoskeletal</conditioncode1>
      <conditioncode2>Other muscular and skeletal disorders</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Inflammatory and Immune System</conditioncode1>
      <conditioncode2>Rheumatoid arthritis</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Autologous modified dendritic cells (DC) pulsed with a mixture of four citrullinated peptide antigens (cit-vimentin
447-455, cit-fibrinogen beta chain 433-441, cit-fibrinogen alpha chain 717-725, cit-collagen type II 1237-1249) designated Rheumavax, will be administered intradermally once to each group of 9 rheumatoid arthritis patients on usual disease modifying drugs in 2 progressive vaccine dose levels (total of 18 vaccinated subjects) in an escalating dose regimen.
Group 1: 1 million DC on day 1 of study
Group 2: 5 million DC on day 1 of study</interventions>
    <comparator>Open label, control (active) group receives standard care i.e. usual disease modifying drugs for the control of rheumatoid arthritis (RA)</comparator>
    <control>Active</control>
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Clinical measures of safety: 
Clinical evaluation and glucose monitoring</outcome>
      <timepoint>baseline, 1 week, monthly for 3 months, and a final evaluation after 6 months in patients and controls</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Laboratory measures of safety: 
Full blood count, biochemical profile. Anti-nuclear antigen, extractable nuclear antigens, radioallergosorbent test (RAST) and fasting lipid profile</outcome>
      <timepoint>baseline, 1 week, monthly for 3 months, and a final evaluation after 6 months in patients and controls. For autoantibodies, RAST and lipids: baseline and 6 months.</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Tolerance: 
Reduction in anti-cyclic citrullinated peptide (CCP) antibody titre and rheumatoid factor titre by analysis of serum. Change in T cell subsets, proliferative and cytokine response in vitro to citrullinated-peptide by analysis of peripheral blood cells. Change in serum cytokine.</outcome>
      <timepoint>baseline, monthly for 3 months, and a final evaluation after 6 months in patients and controls</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Clinical measures of efficacy:
Reduction in health assessment questionnaire score, disease activity score. American College of Rheumatology response score, and lack of progression of hand radiographs.</outcome>
      <timepoint>baseline, monthly for 3 months, and a final evaluation after 6 months in patients and controls. baseline and 6 months for radiographs.</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>1. Age 18-75 years
2. Either sex. It is anticipated that the male: female ratio will be approximately 4:6 for due to the female preponderance with Rheumatoid Arthritis (RA)
3. Subjects who are willing and able to participate in the study for 6 months and from whom written informed consent has been obtained. 
4. Diagnosis of definite RA by American College of Rheumatology criteria with symptoms for at least 3 months
5. In female patients of child-bearing potential, safe contraceptive measures must be used
6. Blood glucose, routine hematology, creatinine, bilirubin and liver function tests within normal limits at entry
7. Must be receiving &lt;10mg/day of prednisone as part of their drug treatment. Patients must have had RA diagnosed and treated by a rheumatologist. Acceptable disease modifying treatment (either as monotherapy or combination therapy) includes methotrexate, salazopyrin, hydroxychloroquine, gold injections, leflunomide, or biologics (etanercept, infliximab, humira or anakinra). Anti-inflammatory medications and local corticosteroid injections are also permissible.
8. Demonstrated anti-CCP antibodies. Rheumatoid factor positive or negative. human leukocyte antigen (HLA)-DR shared epitope positive (HLA-DRB1*0401, 0404, 0405, 0408, 01, 1001, 1401, 1402, 09)</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>75</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>1. Any malignancy
2. History or family history of atopy: eczema, asthma, nasal polyps or allergic rhinitis
3. Positive allergen reactivity (RAST) test 
4. Serious infection within the past 28 days that has not adequately responded to therapy
5. Receipt of any live attenuated vaccines within 4 weeks of study entry.
6. Major surgery within the past 28 days
7. Significant cardiovascular, renal, liver, neurological or skin disease 
8. Females who are pregnant or lactating or who expect to become pregnant within the duration of the study, or who refuse to take contraceptives for the duration of the study
9. Positive serology for Human Immunodeficiency virus (HIV), Hepatitis B virus (HBV), or Hepatitis C virus (HCV)
10. &gt;10 mg prednisone daily  
11. Treatment with cytotoxic or immunomodulatory therapies such as radiotherapy, cyclophosphamide, mycophenolate, tacrolimus, psoralen ultraviolet therapy (PUVA), etretinate, cyclosporine, or azathioprine.
12. History of drug abuse that would interfere with the ability to comply with the study protocol.
13. Any condition judged by the physician to cause this study to be detrimental to the patient.</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Non-randomised trial</allocation>
    <concealment />
    <sequence />
    <masking />
    <assignment />
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 1</phase>
    <anticipatedstartdate>10/11/2009</anticipatedstartdate>
    <actualstartdate />
    <anticipatedenddate />
    <actualenddate />
    <samplesize>18</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Closed: follow-up continuing</recruitmentstatus>
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate />
  </recruitment>
  <sponsorship>
    <primarysponsortype>University</primarysponsortype>
    <primarysponsorname>Uniquest</primarysponsorname>
    <primarysponsoraddress>The University of Queensland
Brisbane QLD 4072</primarysponsoraddress>
    <primarysponsorcountry>Australia</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Government body</fundingtype>
      <fundingname>National Health and Medical Research Council (NHMRC)</fundingname>
      <fundingaddress>GPO Box 1421
Canberra ACT 2601</fundingaddress>
      <fundingcountry>Australia</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>Hospital</sponsortype>
      <sponsorname>Princess Alexandra Hospital</sponsorname>
      <sponsoraddress>199 Ipswich Rd
Buranda Queensland 4102</sponsoraddress>
      <sponsorcountry>Australia</sponsorcountry>
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>This study aims to demonstrate that an immunotherapy made from a patient's own blood cells, (known as Rheumavax) can safely modify (reduce or desensitize) the bodys immune response to a specific rheumatoid arthritis antigen.</summary>
    <trialwebsite />
    <publication>Martin E, OSullivan BJ, Low P and R Thomas. Antigen-specific suppression of a primed immune response by dendritic cells mediated by regulatory T cells secreting interleukin-10. Immunity 2003. 18:155-67. 

Martin E*, Capini C*, Duggan E, Lutzky VP, Stumbles P, Pettit AR, OSullivan BJ and R Thomas. Antigen-specific suppression of established arthritis by dendritic cells deficient in NF-kappa B. Arthritis Rheum 2007, 56:2255-2266

OSullivan BJ, Thompson A, and R Thomas. NF-kappaB as a therapeutic target in autoimmune disease. Exp Opin Ther Targ  2007, 11:111-22</publication>
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Prof Ranjeny Thomas</name>
      <address>Diamantina Institute for Cancer, Immunology and Metabolic Medicine (DI)
University of Queensland
Level 4, R-wing, Building 1
Princess Alexandra Hospital
Brisbane 4102
Qld</address>
      <phone>+61 7 3240 5365</phone>
      <fax />
      <email>ranjeny.thomas@uq.edu.au</email>
      <country>Australia</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title />
      <name>Sr Helen Pahao</name>
      <address>Diamantina Institute for Cancer, Immunology and Metabolic Medicine (DI)
University of Queensland
Level 4, R-wing, Building 1
Princess Alexandra Hospital
Brisbane 4102
Qld</address>
      <phone>+61 7 32402170</phone>
      <fax />
      <email>h.pahao@uq.edu.au</email>
      <country>Australia</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Updating Information</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>